The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Recruiting
18 years - 100 years
Female
1 Location

Brief description of study

The purpose of this study is to compare the efficacy and safety of the experimental drug VB-111 in combination with the standard chemotherapy drug paclitaxel compared to using paclitaxel combined with placebo.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ovarian Cancer
  • Age: 18 years - 100 years
  • Gender: Female

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Histologically confirmed epithelial ovarian cancer and documented disease.
  • Patients must have platinum-resistant disease.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 04 Aug 2024. Study ID: 1901313859 (VB-111-701/GOG-3018)

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team